

Publications by Year

April 10, 2017

Number	Publication	Protocol Number	PMCID
2004			
1	Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. <i>Clinical Infectious Disease</i> . 2004 Oct 15; 39 Suppl 4:S176-180.	BMT CTN 0101	N/A (pre-dates PMCID requirements)
2005			
2	Logan BR. Optimal two-stage randomized Phase II clinical trials. <i>Clinical Trials</i> . 2005 Jan 1; 2(1):5-12.	BMT CTN 0302	N/A (pre-dates PMCID requirements)
3	Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S. BMT CTN Toxicity Committee consensus summary, thrombotic microangiopathy after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> . 2005 Aug 1; 11(8):571-575.	N/A Network publication	N/A (pre-dates PMCID requirements)
2007			
4	Weisdorf D, Carter S, Confer D, Ferrara J, Horowitz M. Blood and Marrow Transplant Clinical Trials Network (BMT CTN): Addressing unanswered questions. <i>Biology of Blood and Marrow Transplantation</i> . 2007 Mar 1; 13(3):257-62; discussion 255-256.	N/A Network publication	N/A (pre-dates PMCID requirements)
5	Keating K. Editorial: Prospective Clinical Trials in BMT Come of Age in the US: The Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> . 2007 Mar 1, 13(3):255-256.	N/A Network publication	N/A (pre-dates PMCID requirements)
6	Ferrara J, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee SJ, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. BMT CTN State of the Science Symposium 2007. <i>Biology of Blood and Marrow Transplantation</i> . 2007 Nov 1; 13:1268-1285.	N/A Network publication	N/A (pre-dates PMCID requirements)
2008			
7	Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, Geller N. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. <i>Clinical Trials</i> . 2008 Jan 1; 5(6):607-616.	BMT CTN 0102	PMC2671015

Number	Publication	Protocol Number	PMCID
8	Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> . 2008 Dec 1; 112(12):4425-4431. Epub 2008 Sep 5.	BMT CTN 0402	PMC2597119
2009			
9	Alousi A, Weisdorf D, Logan B, Bolaños-Meade J, Carter S, DiFronzo N, Pasquini M, Goldstein S, Ho V, Hayes-Lattin B, Wingard J, Horowitz M, Levine J. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute GVHD: A randomized Phase 2 trial from the BMT CTN. <i>Blood</i> . 2009 Jul 16; 114(3):511-517 Epub 2009 May 14.	BMT CTN 0302 PRIMARY MANUSCRIPT	PMC2713466
10	Giralt S, Vesole DH, Somlo G, Krishnan A, Stadtmauer E, McCarthy P, Pasquini MC, BMT CTN Multiple Myeloma Working Group. Re: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> . 2009 Jul 01; 101(13):964; author reply 966-967. Epub 2009 Jun 17. [Comment on: <i>Journal of the National Cancer Institute</i> 101(2):100-106, 2009].	BMT CTN 0102	N/A Correspondence
2010			
11	Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE, Weisdorf D. Mycophenolate pharmacokinetics and association with response to acute GVHD treatment from the BMT CTN. <i>Biology of Blood and Marrow Transplantation</i> . 2010 Mar 1; 16(3):421-429.	BMT CTN 0302	PMC3104501
12	Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D, On behalf of the BMT CTN. Graft-versus-host disease treatment: predictors of survival. <i>Biology of Blood and Marrow Transplantation</i> . 2010 Dec 1; 16(12):1693-1699. Epub 2010 Jun 9.	BMT CTN 0302	PMC2955996
13	Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; BMT CTN. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> . 2010 Dec 9; 116(24):5111-5118. Epub 2010 Sep 8.	BMT CTN 0101 PRIMARY MANUSCRIPT	PMC3012532

Number	Publication	Protocol Number	PMCID
14	Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biological and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the BMT CTN, March 2010. <i>Biology of Blood and Marrow Transplantation</i> . 2011 Mar 1; 17(3):291-299. Epub 2010 Oct 27.	BMT CTN 0301	PMC3053041
15	Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG. Autologous versus reduced intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. <i>Biology of Blood and Marrow Transplantation</i> . 2011 Jul 1; 17(7):1051-1057. Epub 2010 Nov 10.	BMT CTN 0202 PRIMARY MANUSCRIPT	PMC3114272
16	Horowitz EM, Horowitz MM, DiFronzo NL, Kohn DB, Heslop HE, BMT CTN State of the Science Cell and Gene Therapy Committee. Guidance for developing Phase II cell therapy trial proposals for consideration by the BMT CTN. <i>Biology of Blood and Marrow Transplantation</i> . 2011 Feb 1; 17(2):192-196. Epub 2010 Dec 21.	N/A Network publication	PMC3387575
2011			
17	Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ. Low risk of chronic graft-versus-host disease and relapse associated with T cell depleted peripheral blood stem cell transplantation for acute myeloid leukemia in first remission: results of the BMT CTN protocol 0303. <i>Biology of Blood and Marrow Transplantation</i> . 2011 Sep 1; 17(9):1343-1351. Epub 2011 Feb 12.	BMT CTN 0303 PRIMARY MANUSCRIPT	PMC3150599
18	Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June C, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic: workshop of the BMT CTN sub-committee on cell and gene therapy. <i>Molecular Therapy</i> . 2011 Mar 1; 19(3): 432-438. Epub 2011 Mar 1.	N/A Network publication	PMC3048197
19	Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV. Alternative donor transplantation: results of parallel Phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts. <i>Blood</i> . 2011 Jul 14; 118(2):282-288. Epub 2011 Apr 28.	BMT CTN 0603 / BMT CTN 0604 PRIMARY MANUSCRIPT	PMC3138683

Number	Publication	Protocol Number	PMCID
20	Denzen EM, Burton Santibáñez ME, Moore H, Foley A, Gersten I, Gurgol C, Majhail NS, Spellecy R, Horowitz MM, Murphy EA. Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials. <i>Biology of Blood and Marrow Transplantation</i> . 2012 Feb 1; 18(2):183–189. Epub 2011 Jul 30.	N/A Network publication	PMC3242929
21	Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ. Characteristics of CliniMACS(®) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-BMT CTN Protocol 0303. <i>Biology of Blood and Marrow Transplantation</i> . 2012 May 1; 18(5):690-697. Epub 2011 Aug 26.	BMT CTN 0303	PMC3762249
22	Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giral S, Maloney DG. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a Phase 3 biological assignment trial. <i>Lancet Oncology</i> . 2011 Dec 1; 12(13):1195-1203. Epub 2011 Sep 29.	BMT CTN 0102 PRIMARY MANUSCRIPT	PMC3611089
2012			
23	Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the Phase II study from the BMT CTN. <i>Biology of Blood and Marrow Transplantation</i> . 2012 Aug 1; 18(8):1265-1272. Epub 2012 Feb 16.	BMT CTN 0601	PMC3618440
24	Levine J, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JLM, Ho VT, Weisdorf DJ, Paczesny S. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a BMT CTN study. <i>Blood</i> . 2012 Apr 19; 119(16):3854-3860. Epub 2012 Mar 1.	BMT CTN 0302	PMC3335389

Number	Publication	Protocol Number	PMCID
25	Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty J, Adams R, Ewell M, Leifer E, Gersten I, Carter S, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer D, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. <i>Biology of Blood and Marrow Transplantation</i> . 2012 July 1; 18(7):1007-1011. Epub 2012 Apr 27.	BMT CTN 0301	PMC3677744
26	McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Sexton M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Phase III study of lenalidomide versus placebo after HCT for multiple myeloma. <i>New England Journal of Medicine</i> . 2012 May 10; 366(19):1770-1781.	BMT CTN 0704 / CALGB 100104 / ECOG 100104 PRIMARY MANUSCRIPT	PMC3744390
27	Pasquini M, Devine S, Mendizabal A, Baden L, Wingard J, Lazarus H, Appelbaum F, Keever-Taylor C, Horowitz M, Carter S, O'Reilly R, Soiffer R. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> . 2012 Sep 10; 30(26):3194-3201. Epub 2012 Aug 6.	BMT CTN 0303	PMC3434978
28	Logan BR, Zhang MJ. The use of group sequential designs with common competing risks tests. <i>Statistics in Medicine</i> . 2013 Mar 15; 32(6):899-913. Epub 2012 Sep 4.	N/A Network publication	PMC3574186
29	Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. <i>Journal of Immunology</i> . 2012 Nov 15; 189(10):5082-5088. Epub 2012 Oct 17.	BMT CTN 0201	PMC3490031
30	Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Peripheral blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> . 2012 Oct 18; 367(16):1487-1496.	BMT CTN 0201 PRIMARY MANUSCRIPT	PMC3816375

Number	Publication	Protocol Number	PMCID
31	Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L. Lymphocyte phenotype during therapy for acute graft versus host disease: a brief report from BMT-CTN 0302. <i>Biology of Blood and Marrow Transplantation</i> . 2013 Mar 1; 19(3):481-485. Epub 2012 Dec 11.	BMT CTN 0302	PMC3653300
2013			
32	Vose JM, Carter S, Burns LJ, Ayala E, Press O, Moskowitz CH, Stadtmauer EA, Mineishi S, Ambinder RF, Fenske TS, Horowitz MM, Fisher RI, Tomblyn M. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, melphalan (BEAM) compared with 131-Iodine tositumomab/BEAM with autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma: results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0401 trial. <i>Journal of Clinical Oncology</i> . 2013 May 1; 31(13):1662-1668. Epub 2013 Mar 11.	BMT CTN 0401 PRIMARY MANUSCRIPT	PMC3635682
33	Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM. Anatomy of a successful practice-changing study: a Blood and Marrow Transplant Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration. <i>Biology of Blood and Marrow Transplantation</i> . 2013 Jun 01; 19(6):858-859. Epub 2013 Mar 29.	BMT CTN 0704 / CALGB 100104 / ECOG 100104	N/A
34	Mauskopf J, Chirila C, Graham J, Gersten I, Maziarz R, Baden L, Bolanos-Meade J, Brown J, Walsh T, Horowitz M, Kurtzberg J, Marr K and Wingard J, Leather H. Cost-effectiveness analysis of voriconazole compared With fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. <i>American Journal Health-System Pharmacy</i> . 2013 Sep 1; 70(17):1518-1527.	BMT CTN 0101	PMC4019750
35	Switzer GE, Bruce JG, Harrington D, Haagenson M, Drexler R, Foley A, Confer D, Bishop M, Anderlini P, Rowley S, Leitman SF, Anasetti C, Wingard JR. Health-related QoL of bone marrow versus PBSC donors: a pre-specified subgroup analysis from a phase III RCT BMT CTN protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> . 2014 Jan 1; 20(1):118-127. Epub 2013 Nov 1.	BMT CTN 0201	PMC3978600
36	Ferrara J. Blood and Marrow Transplant Clinical Trials Network: Progress since the State of the Science Symposium 2007. <i>Biology of Blood and Marrow Transplantation</i> . 2014 Feb 1; 20(2):149-153. Epub 2013 Nov 12.	N/A Network Publication	PMC24239651

Number	Publication	Protocol Number	PMCID
2014			
37	Roth JA, Bensink ME, O'Donnell PV, Brunstein CG, Fuchs EJ, Eapen M, Ramsey SD. Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. <i>Journal of Comparative Effectiveness Research</i> . 2014 Mar 1; 3(2):135-144. Epub 2014 Mar.	BMT CTN 1101	PMC4036637
38	Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, DiFronzo NL, Ferrara JL, Giralto S, Madtes DK, Drexler R, White ES, Cooke KR. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> . 2014 Jun 1; 20(6): 858-864. Epub 2014 Mar 7	BMT CTN 0403 PRIMARY MANUSCRIPT	PMC4128626
39	Eapen M, O'Donnell P, Brunstein C, Barowski K, Mendizabal A, Fuchs E. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> . 2014 Oct 1; 20(10):1485-1492. Epub 2014 May 23.	BMT CTN 0603/0604 and 1101	PMC4163123
40	Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail NS, Wood W, Rizzo JD, Geller NL, Kitko C, Faber E, Abidi MH, Slater S, Horowitz MM, Lee SJ. Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trial Network (BMT CTN) 0902. <i>Biology of Blood and Marrow Transplantation</i> . 2014 Oct 1; 20(10):1530-1536. Epub 2014 Jun 6.	BMT CTN 0902 PRIMARY MANUSCRIPT	PMC4163109
41	Saber W, Le-Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum F, Horowitz M, Nakamura R, Cutler C. Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> . 2014 Oct 1; 20(10):1566-1572. Epub 2014 Jun 24.	BMT CTN 1102	PMC4169902

Number	Publication	Protocol Number	PMCID
42	Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi M, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti A. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. <i>Journal of Clinical Oncology</i> . 2014 Aug 1; 32(22): 2365-2372. Epub 2014 Jun 30.	BMT CTN 0201	PMC4180368
43	Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan W, Pasquini M, MacMillan M, Hsu J, Waller E, Grupp S, McCarthy P, Wu J, Hu Z, Carter S, Horowitz M, Antin J. Tacrolimus/Sirolimus versus Tacrolimus/Methotrexate as GVHD Prophylaxis after Matched, Related Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> . 2014 Aug 21; 124(8):1372-1377. Epub 2014 Jun 30.	BMT CTN 0402 PRIMARY MANUSCRIPT	PMC4141519
44	Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase III Clinical Trial Steroids/Mycophenolate Mofetil vs Steroids/Placebo as Therapy for Acute Graft-versus-Host Disease: BMT CTN 0802. <i>Blood</i> . 2014 Nov 20; 124(22):3221-3227. Epub 2014 Aug 28.	BMT CTN 0802 PRIMARY MANUSCRIPT	PMC4239331
45	Wagner JE Jr., Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J. One-versus Two-Unit Cord Blood Transplant for Leukemia. <i>New England Journal of Medicine</i> . 2014 Oct 30; 371(18):1685-1694.	BMT CTN 0501 PRIMARY MANUSCRIPT	PMC4257059
46	Atallah E, Bylow K, Troy J, Saber W. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): The emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). <i>Current Hematologic Malignancy Reports</i> . 2014 Mar 1; 9(1):57-65. Epub 2014 Mar.	BMT CTN 1102	PMC4031643
47	Howard A, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR. Recommendations for Donor HLA Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood Marrow Transplantation</i> . 2015 Jan; 21(1):4-7. Epub 2014 Sep 30.	N/A Network Publication	PMC4272893

Number	Publication	Protocol Number	PMCID
48	Appelbaum F, Anasetti C, Antin J, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee S, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard J, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014. <i>Biology of Blood and Marrow Transplantation</i> 2015 Feb; 21(2): 202-224. Epub 2014 Oct 15	N/A Network Publication	PMC4426907
49	Levine JE , Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara JLM for the Blood and Marrow Transplant Clinical Trials Network. A Prognostic Score for Acute Graft-Versus-Host Disease Based on Biomarkers: A Multicentre Study. <i>Lancet Haematology</i> .2015 Jan; 2(1): 21-29. Epub 2014 Dec 22.	BMT CTN 0302	PMC4340092
2015			
50	MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J., Ferrara JLM, Jones R, Arora M, Blazar, BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ . A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> . 2015 Apr; 21(4): 761-767. Epub 2015 Jan 10.	BMT CTN 0302 and BMT CTN 0802	PMC4359643
51	Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltis-Mortari A, Weisdorf DJ. Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute-Graft-Versus-Host Disease: Results from BMT CTN 0302 and 0802. <i>Biology of Blood and Marrow Transplantation</i> . 2015 Jun 1; 21(6) 1029-1036., Epub 2015 Mar 7	BMT CTN 0302 and BMT CTN 0802	PMC4426052
52	Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, Burns LJ, Dalal JD, Freytes CO, Gupta V, Inamoto Y, Lazarus HM, LeMaistre CF, Steinberg A, Swajcer D, Wingard JR, Wirk B, Wood WA, Joffe S, Hahn TE, Loberiza FR, Anasetti C, Horowitz MM, Lee SJ. Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> . 2015 Oct 1. 21 (10): 1815-1822. [Epub 2015 Jun 11.]	BMT CTN 0201	PMC4568172

53	Anderlini P; Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. <i>Lancet Haematology</i> . 2015 Sep; 2(9): e367-375. Epub 2015 Sep 2.	BMT CTN 0301 PRIMARY MANUSCRIPT	PMC4861234
54	Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti. Infections after Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> . 2016 Feb; 22(2): 359-370., Epub 2015 Sep 25.	BMT CTN 0201	PMC4716871 (Available February 1, 2017)
55	Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A ¹ , Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turrison I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E: American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> . 2015 Dec; 21(12): 2039-2051., Epub 2015 Sep 30.	Network Publication	PMC4757494
56	Wood WA, MD, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). <i>Cancer</i> . 2016 Jan 1; 122(1): 91-98., Epub 2015 Oct 6.	BMT CTN 0902	PMC4707096

57	Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of Clinical Oncology. 2015 Dec 10; 33(35): 4167-4175., Epub 2015 Nov 2.	CALGB 100103/BMT CTN 0502	PMC4658453
----	---	---------------------------------	------------

2016			
58	Burns LJ, Logan BR, Chitphakdithai P, Miller JP, Drexler R, Spellman S, Switzer GE, Wingard JR, Anasetti C, Confer DL. Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Bone Marrow: A Prespecified Analysis from the Phase III BMT CTN Protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> . 2016 Jun; 22(6): 1108-1116., Epub 2016 Mar 21.	BMT CTN 0201	PMC4867293 (Available on June 1, 2017)
59	Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood Marrow Transplantation</i> . 2016 Aug; 22(8): 1440-8., Epub 2016 Apr 23.	BMT CTN 0701 Primary Manuscript	PMC4949103 (Available August 1, 2017)
60	Hope W, Walsh T, Goodwin J, Peloquin C, Howard A, Kurtzberg J, Mendizabal A, Confer D, Bulitta J, Baden L, Neely M, Wingard J. Voriconazole pharmacokinetics following hematopoietic Stem Cell Transplantation: Results from the BMT CTN 0101 Trial. <i>Journal of Antimicrobial Chemotherapy</i> . 2016 Aug; 71(8): 2234-2240., Epub 2016 Apr 27.	BMT CTN 0101	PMC4954923 (Available August 1, 2017)
61	D'Souza A, Pasquini M, Logan B, Giralto S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Vesole D, Stadtmauer E, Maloney D, Parameswaran H. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. <i>British Journal of Haematology</i> . 2016 Jun 13 [Epub ahead of print].	0102	PMC5154782 (Available December 13, 2017)
62	Alvarnas JC, Le-Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous Hematopoietic Cell Transplantation for HIV-related Lymphoma: Results of the (BMT CTN) 0803/(AMC) 071 Trial. <i>Blood</i> . 2016 Aug 25; 128(8): 1050-1058., Epub 2016 Jun 13.	BMT CTN 0803	PMC5000843 (Available August 25, 2017)
63	Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network.. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> . 2016 Oct; 22(10): 1747-1457., Epub 2016 Jul 11.	BMT CTN 10 Year Manuscript	PMC5027144 (Available October 1, 2017)

64	Jim HSL, Sutton SK, Small BJ, Jacobsen PB, Wood WA, Knight JM, Majhail NS, Syrjala KL, Lee SJ. Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data. <i>Biology of Blood and Marrow Transplantation</i> . 2016 Nov; 22(11): 2077-2083., Epub 2016 Aug 15.	0902	PMC5068568 (Available November 1, 2017)
65	O'Donnell PV, Eapen M, Horowitz MM, Logan BR, DiGilio A, Brunstein C, Fuchs E, Flowers ME, Salit R, , Raj K, Pagliuca A, Bradstock K, Granata A, Castagna L, Fürst S, Blaise D. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. <i>Bone Marrow Transplantation</i> . 2016 Dec; 51(12): 1599-1601., Epub 2016 Aug 15.	1101	PMC5143194 (Available December 1, 2017)
66	Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA,, Jim HS, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <i>Biology of Blood and Marrow Transplantation</i> . 2016 Dec; 22(12): 2256-2263., Epub 2016 Aug 23.	0902	PMC5116244 (Available December 1, 2017)
67	Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus H, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, Horowitz M, Walters MC, Kamani N. A BMT CTN Phase II Trial of Unrelated Donor Marrow Transplantation for Children with Severe Sickle Cell Disease. <i>Blood</i> . 2016 Nov 24; 128(21): 2561-2567., Epub 2016 Sept 13.	0601	PMC5123194 (Available November 24, 2017)
68	Wingard J, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight J, Jacobsen PB, Jim H, Majhail NS, Syrjala K, Rizzo JD, Lee S. Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). <i>Biology of Blood and Marrow Transplantation</i> . 2017 Jan; 23(1): 161-164., Epub 2016 Oct 11.	0902	PMC5182134 (Available January 1, 2018)
69	Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW. Plasma Biomarkers of risk for death in a Multicenter Phase 3 Trial with Uniform Transplant Characteristics Post-Allogeneic HCT. <i>Blood</i> . 2017 Jan 12; 129(2): 162-170. Epub 2016 Nov 8.	0402	PMID: 27827824 [PubMed - as supplied by publisher]

70	Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw B, Confer D, Horowitz MM, Anasetti C. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. <i>JAMA Onc.</i> 2016 Dec 1; 2(12): 1583-1589.	BMT CTN 0201	PMC5145732 (Available December 1, 2017)
71	Ravandi F, Othus M, O'Brien S, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian H, Radich JP, Erba HP, Appelbaum FR. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL <i>Blood Advances.</i> 1(3):250-259. Epub 2016 Dec 27.	SWOG S0410 and S0805	
72	Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative vs. reduced intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. <i>Journal of Clinical Oncology.</i> 2017 Apr 10; 35(11); 1154-1161. Epub 2017 Feb 13.	BMT CTN 0901	PMID 28380315